{"id":34889,"date":"2017-11-28T17:27:55","date_gmt":"2017-11-28T15:27:55","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=34889"},"modified":"2017-11-28T17:27:55","modified_gmt":"2017-11-28T15:27:55","slug":"revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","title":{"rendered":"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn"},"content":{"rendered":"<p style=\"text-align: justify;\">El passat dimecres 22 de novembre va tenir lloc al COFB el curs <strong><em>Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics<\/em><\/strong> adre\u00e7at a farmac\u00e8utics comunitaris, d&#8217;hospitals, de centres d&#8217;atenci\u00f3 prim\u00e0ria i de l&#8217;administraci\u00f3 sanit\u00e0ria.<\/p>\n<p style=\"text-align: justify;\">El curs tenia per <strong>objectius principals<\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li style=\"text-align: justify;\">Saber quins s\u00f3n els <strong>objectius terap\u00e8utics<\/strong> en diverses patologies.<\/li>\n<li>Con\u00e8ixer les <strong>estrat\u00e8gies noves per tractar la psoriasi<\/strong>, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn.<\/li>\n<li>Millorar la <strong>pr\u00e0ctica cl\u00ednica<\/strong> i fer un <strong>millor \u00fas de les noves estrat\u00e8gies terap\u00e8utiques.<\/strong><\/li>\n<li style=\"text-align: justify;\"><strong>Aprendre<\/strong> de l&#8217;experi\u00e8ncia personal en l&#8217;<strong>\u00fas de f\u00e0rmacs biol\u00f2gics<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><div class=\"box info\"> Els <strong>f\u00e0rmacs biol\u00f2gics s\u00f3n el present i el futur del tractament de moltes malalties<\/strong> com el <strong>c\u00e0ncer<\/strong>, l&#8217;<strong>esclerosi m\u00faltiple<\/strong>, l&#8217;<strong>artritis reumatoide i psori\u00e0sica<\/strong> o la<strong> malaltia de Crohn<\/strong>. <\/div><\/p>\n<p style=\"text-align: justify;\">La <strong>jornada <\/strong>es va iniciar amb la confer\u00e8ncia<strong> &#8220;Artritis psori\u00e0sica: immunomoduladors i import\u00e0ncia d&#8217;alternatives terap\u00e8utiques&#8221; <\/strong>a c\u00e0rrec del Dr. Agust\u00ed Sellas, reumat\u00f2leg de la Unitat de Reumatologia de l&#8217;Hospital Universitari Vall d&#8217;Hebron. En aquesta confer\u00e8ncia <strong>es va abordar l&#8217;epidemiologia de l&#8217;Artritis Psori\u00e0sica<\/strong> i la seva <strong>freq\u00fc\u00e8ncia a estudis poblacionals generals<\/strong>, fent refer\u00e8ncia als patrons cl\u00ednics i a la valoraci\u00f3 cl\u00ednica de l&#8217;activitat.<\/p>\n<figure id=\"attachment_34912\" aria-describedby=\"caption-attachment-34912\" style=\"width: 794px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-05.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"size-full wp-image-34912 \" title=\"El doctor Agust\u00ed Sellas i les doctores Anna L\u00f3pez i Luc\u00eda M\u00e1rquez, acompanyats de la cap del Departament de Formaci\u00f3 i Desenvolupament Professional del COFB, Cristina Rodr\u00edguez.\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-05.jpg\" alt=\"El doctor Agust\u00ed Sellas i les doctores Anna L\u00f3pez i Luc\u00eda M\u00e1rquez, acompanyats de la cap del Departament de Formaci\u00f3 i Desenvolupament Professional del COFB, Cristina Rodr\u00edguez.\" width=\"794\" height=\"529\" \/><\/a><figcaption id=\"caption-attachment-34912\" class=\"wp-caption-text\">El doctor Agust\u00ed Sellas i les doctores Anna L\u00f3pez i Luc\u00eda M\u00e1rquez, acompanyats de la cap del Departament de Formaci\u00f3 i Desenvolupament Professional del COFB, Cristina Rodr\u00edguez.<\/figcaption><\/figure>\n<p style=\"text-align: justify;\">Tot seguit va ser el torn de la confer\u00e8ncia<strong>\u00a0\u201cPsoriasi: objectiu, persist\u00e8ncia i \u00fas de biosimilars&#8221;<\/strong> que va anar c\u00e0rrec de la Dra. Anna L\u00f3pez, del Servei de Dermatologia de l&#8217;Hospital de la Santa Creu i Sant Pau. La Dra. L\u00f3pez va fer refer\u00e8ncia a l&#8217;<strong>evoluci\u00f3 dels tractaments de la psoriasi<\/strong>, als objectius terap\u00e8utics i tamb\u00e9 a algunes mesures d&#8217;avaluaci\u00f3 de la psoriasi com: Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), o el Physicians\u2019 Global Assessment (PGA), entre d&#8217;altres.<\/p>\n<p style=\"text-align: justify;\">Un altre dels temes que es va tractar durant la confer\u00e8ncia va ser el dels <strong>f\u00e0rmacs biosimilars. <\/strong>Es tracta de <strong>productes biol\u00f2gics<\/strong> molt similars al producte de refer\u00e8ncia. El biol\u00f2gic biosimilar \u00e9s creat mitjan\u00e7ant \u201cenginyeria reversa\u201d, a partir de la informaci\u00f3 coneguda sobre el producte de refer\u00e8ncia. Els f\u00e0rmacs biol\u00f2gics s\u00f3n produ\u00efts per l\u00ednies cel\u00b7lulars \u00faniques mitjan\u00e7ant bioenginyeria.<\/p>\n<p style=\"text-align: justify;\">Com a conclusions, la Dra. L\u00f3pez va destacar que <strong>els f\u00e0rmacs biosimilars poden reduir el cost comparat amb els f\u00e0rmacs de refer\u00e8ncia<\/strong> i que la situaci\u00f3 actual permet l\u2019extrapolaci\u00f3 d\u2019indicacions per part de les ag\u00e8ncies reguladores. Tamb\u00e9 que cal una definici\u00f3 m\u00e9s acurada sobre la intercanviabilitat i valorar la implicaci\u00f3 en la interpretaci\u00f3 de canvis en efici\u00e8ncia \u00a0i seguretat, important pel metge prescriptor. L&#8217;objectiu \u00e9s aconseguir el blanquejament del pacient<strong> (efic\u00e0cia)<\/strong>, mantenir el pacient blanquejat el m\u00e0xim de temps possible <strong>(superviv\u00e8ncia)<\/strong>, mantenir el pacient blanquejat amb el menor cost possible <strong>(efici\u00e8ncia) <\/strong>i mantenir el pacient amb la millor qualitat de vida possible. La probabilitat d&#8217;\u00e8xit \u00e9s inversament proporcional a la complexitat del pacient.<\/p>\n<figure id=\"attachment_34914\" aria-describedby=\"caption-attachment-34914\" style=\"width: 689px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-22.jpg\"><img decoding=\"async\" class=\"size-full wp-image-34914 \" title=\"El Dr. Agust\u00ed Sellas, durant la confer\u00e8ncia &quot;Artritis psori\u00e0sica: immunomoduladors i import\u00e0ncia d'alternatives terap\u00e8utiques&quot;.\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-22.jpg\" alt=\"El Dr. Agust\u00ed Sellas, durant la confer\u00e8ncia &quot;Artritis psori\u00e0sica: immunomoduladors i import\u00e0ncia d'alternatives terap\u00e8utiques&quot;.\" width=\"689\" height=\"459\" \/><\/a><figcaption id=\"caption-attachment-34914\" class=\"wp-caption-text\">El doctor Agust\u00ed Sellas, durant la confer\u00e8ncia &#8220;Artritis psori\u00e0sica: immunomoduladors i import\u00e0ncia d&#8217;alternatives terap\u00e8utiques&#8221;.<\/figcaption><\/figure>\n<p style=\"text-align: justify;\">Finalment, la darrera confer\u00e8ncia va ser <strong>\u201cMalaltia de Crohn: definici\u00f3 del tractament ideal i noves mol\u00e8cules per tractar-la\u201d\u00a0<\/strong>i va anar a c\u00e0rrec de la Dra. Luc\u00eda M\u00e1rquez, digest\u00f2loga adjunta de la Unitat de Malaltia Inflamat\u00f2ria Intestinal, del Servei Digestiu de l\u2019Hospital del Mar.<\/p>\n<p style=\"text-align: justify;\">Al llarg de l&#8217;exposici\u00f3 es va explicar qu\u00e8 \u00e9s una <strong>Malaltia Inflamat\u00f2ria Intestinal (MII). <\/strong>Es tracta d&#8217;una malaltia cr\u00f2nica d\u2019etologia multifactorial, que afecta el tracte gastrointestinal amb un curs recurrent. Tamb\u00e9 es va exposar en qu\u00e8 consisteix la <strong>colitis ulcerosa<\/strong> (afectaci\u00f3 cont\u00ednua des del recte limitada a la mucosa) i la <b>malaltia de Crohn <\/b>(afectaci\u00f3 de qualsevol tram del tracte digestiu, transmural i freq\u00fcentment malaltia perianal).<\/p>\n<p style=\"text-align: justify;\">La colitis ulcerosa i la malaltia de Crohn s\u00f3n <strong>malalties complexes i polig\u00e8niques<\/strong> i depenen de: <strong>factors ambientals<\/strong>, <strong>barrera intestinal<\/strong>, <strong>factors gen\u00e8tics<\/strong>, <strong>flora intestinal<\/strong> i <strong>immunitat innata-adquirida<\/strong>.<\/p>\n<p><div class=\"box note\"> El <strong>tractament<\/strong> <strong>de la malaltia de Crohn<\/strong> \u00e9s <strong>diferent segons:<\/strong><\/p>\n<ul>\n<li>la gravetat del brot<\/li>\n<li>l\u2019extensi\u00f3 de l\u2019afectaci\u00f3<\/li>\n<li>el patr\u00f3<\/li>\n<li>les manifestacions extraintestinals<\/li>\n<li>la fase d\u2019activitat<\/li>\n<li>si est\u00e0 inactiva (tractament de manteniment)<\/li>\n<li>els antecedents patol\u00f2gics (neopl\u00e0sies, infeccions&#8230;) <\/div><\/li>\n<\/ul>\n<p>Per concloure, la Dra. L. M\u00e1rquez va fer refer\u00e8ncia tamb\u00e9 a les <strong>noves estrat\u00e8gies del tractament de la malaltia de Crohn (una malaltia d\u2019incid\u00e8ncia creixent als pa\u00efsos occidentals, lligada a la industrialitzaci\u00f3)<\/strong>, la necessitat d\u2019establir amb la m\u00e0xima certesa possible l\u2019activitat real de la malaltia (molts pacients asimptom\u00e0tics amb activitat i simptom\u00e0tics sense lesions) i la necessitat d&#8217;incorporar als assajos cl\u00ednics mesures d\u2019activitat objectives.<\/p>\n<p style=\"text-align: right;\">\u00a0 <strong>Amb la col\u00b7laboraci\u00f3 de:<\/strong><\/p>\n<p style=\"text-align: right;\"><a href=\"https:\/\/www.janssen.com\/es\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"wp-image-41846 alignright\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/Janssen.jpg\" alt=\"\" width=\"172\" height=\"84\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Altres informacions relacionades recollides al Blog:<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blog.cofb.cat\/jornada-formativa-sobre-psoriasi-el-paper-del-farmaceutic-en-la-millora-del-seu-control\/\" target=\"_blank\" rel=\"noopener\">Jornada formativa sobre psoriasi i el paper del faramc\u00e8utic en la millora del seu control (Setembre 2017)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/arriba-barcelona-la-campanya-de-conscienciacio-activacio-aclareix-la-psoriasi\/\" target=\"_blank\" rel=\"noopener\">Arriba a Barcelona la campanya de conscienciaci\u00f3 i activaci\u00f3 &#8220;Aclareix la psoriasi&#8221; (Juny 2017)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/els-farmaceutics-actualitzen-coneixements-en-melatonina-dermatitis-atopica\/\" target=\"_blank\" rel=\"noopener\">Els farmac\u00e8utics actualitzen coneixements en melatonina i dermatits at\u00f2pica (Juny 2017)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/lexposicio-psoriasi-el-que-la-pell-amaga-arriba-terrassa-per-sensibilitzar-sobre-la-gravetat-daquesta-malaltia\/\" target=\"_blank\" rel=\"noopener\">L&#8217;exposici\u00f3 &#8220;Psoriasi, el que la pell amaga&#8221; arriba a Terrassa per a sensibilitzar sobre la gravetat d&#8217;aquesta malaltia (Octubre 2016)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/5-de-maig-jornada-sobre-psoriasi-i-artritis-psoriasica-a-barcelona\/\" target=\"_blank\" rel=\"noopener\">5 de maig: jornada sobre psoriasi i artritis psor\u00e0sica a Barcelona (Maig 2016)<\/a><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El passat dimecres 22 de novembre va tenir lloc al COFB el curs Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics adre\u00e7at a farmac\u00e8utics comunitaris, d&#8217;hospitals, de centres d&#8217;atenci\u00f3 prim\u00e0ria i de l&#8217;administraci\u00f3 sanit\u00e0ria. El curs tenia per objectius principals: Saber quins s\u00f3n els objectius terap\u00e8utics en diverses patologies. Con\u00e8ixer les estrat\u00e8gies [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[209,2929,18,54,70,222,231],"class_list":["post-34889","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-artritis-psoriasica","tag-biologics","tag-cofb","tag-farmacs","tag-formacio","tag-malaltia-de-crohn","tag-psoriasi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#039;artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#039;artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-28T15:27:55+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn\",\"datePublished\":\"2017-11-28T15:27:55+00:00\",\"dateModified\":\"2017-11-28T15:27:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\"},\"wordCount\":979,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"artritis psori\u00e0sica\",\"biol\u00f2gics\",\"COFB\",\"f\u00e0rmacs\",\"Formaci\u00f3\",\"malaltia de crohn\",\"psoriasi\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\",\"name\":\"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2017-11-28T15:27:55+00:00\",\"dateModified\":\"2017-11-28T15:27:55+00:00\",\"description\":\"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","og_locale":"ca_ES","og_type":"article","og_title":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics","og_url":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2017-11-28T15:27:55+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"5 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn","datePublished":"2017-11-28T15:27:55+00:00","dateModified":"2017-11-28T15:27:55+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/"},"wordCount":979,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage"},"thumbnailUrl":"","keywords":["artritis psori\u00e0sica","biol\u00f2gics","COFB","f\u00e0rmacs","Formaci\u00f3","malaltia de crohn","psoriasi"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","url":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","name":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage"},"thumbnailUrl":"","datePublished":"2017-11-28T15:27:55+00:00","dateModified":"2017-11-28T15:27:55+00:00","description":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat dimecres 22 de novembre va tenir lloc al COFB el curs Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics adre\u00e7at a farmac\u00e8utics comunitaris, d&#8217;hospitals, de centres d&#8217;atenci\u00f3 prim\u00e0ria i de l&#8217;administraci\u00f3 sanit\u00e0ria. El curs tenia per objectius principals: Saber quins s\u00f3n els objectius terap\u00e8utics en diverses patologies. Con\u00e8ixer les estrat\u00e8gies [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/34889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=34889"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/34889\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=34889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=34889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=34889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}